COST-EFFECTIVENESS ANALYSIS USE OF ANTIBIOTICS IN COVID-19 PATIENTS

DOI: https://doi.org/10.31596/cjp.v7i2.245

Mera Putri Pratitis(1), Yulia Pratiwi(2*), Wildayanti Wildayanti(3), Cita Nuryatunnisa(4)

(1) Institut Teknologi Kesehatan Cendekia Utama Kudus
(2) Institut Teknologi Kesehatan Cendekia Utama Kudus
(3) Institut Teknologi Kesehatan Cendekia Utama Kudus
(4) Institut Teknologi Kesehatan Cendekia Utama Kudus
(*) Corresponding Author

Abstract


Corona Virus Disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and can cause respiratory tract infections. This disease requires a large cost in the management process. This has an impact on the economic condition of the patient, so it is necessary to identify pharmacoeconomic studies. One of the pharmacoeconomic methods that can be used is Cost-Effectiveness Analysis, this method is used to select and calculate the best therapeutic costs and benefits (outcomes) for several therapeutic options for the same purpose. This study aims to analyze the cost-effectiveness of using the antibiotics azithromycin and levofloxacin in the treatment of COVID-19 at the Fastabiq Sehat General Hospital, PKU Muhammadiyah Pati. Sampling in this study was carried out by purposive sampling. Samples obtained according to the inclusion criteria were 57 patients. The data was taken from the patient's medical records, pharmaceutical installations, and finances including characteristics, drug use data, and data on total medical costs. Costs are reviewed from direct medical costs (direct medical costs). The effectiveness of therapy for COVID-19 patients at Fastabiq Sehat General Hospital PKU Muhammadiyah Pati reached the target in the antibiotic azithromycin group with a percentage (80.76%). The ACER value showed the antibiotic azithromycin was Rp.97,809 and levofloxacin was Rp. 127,285. The therapy model that can be used as a standard treatment for COVID-19 is azithromycin at the RSU Fastabiq Sehat, PKU Muhammadiyah Pati.

Keywords


Antibiotics, Cost Effectiveness analysis, Covid-19

Full Text:

PDF

Article Metrics

Abstract viewed : 42 times | PDF files downloaded : 31 times

References


Andayani, T.M. (2013) Farmakoekonomi Prinsip Dan Metodologi. Yogyakarta: Bursa Ilmu Karangkajen.

Ardizzone, A. et al. (2022) ‘Neurofibromatosis: New Clinical Challenges in the Era of COVID-19’, Biomedicines, 10(5), pp. 1–16.

Bacharier, L.B. (2015) ‘Early Administration Of Azithromycin And Prevention Of Severe Lower Respiratory Tract Illnesses In Preschool Children With History Of Such’, Journal Of American Medical Association, 17(354), pp. 2034–2044.

BADAN POM (2020) Langkah Strategi Badan POM Dalam Penanganan Obat COVID-19. Jakarta.

Burhan, E. et al. (2020) ‘Pneumonia COVID-19’, Journal of the American Pharmacists Association, 55(5).

Donsu, Y.C. and Hasmono, D. (2020) ‘Tinjauan Azitromisin Pada Penyakit Virus Korona 2019 (COVID-19)’, Pharmacon: Jurnal Farmasi Indonesia, 17(2), pp. 133–147.

Dyussenbayev, A. (2017) ‘Age Periods Of Human Life. ’, Advances in Social Sciences Research Journal, 4.

Elviani, R., Anwar, C. and Januar Sitorus, R. (2021) ‘Gambaran Usia Pada Kejadian Covid-19’, Jambi Medical Journal “Jurnal Kedokteran Dan Kesehatan", 9(1), pp. 204–209.

Guo, W. et al. (2020) ‘Diabetes is a risk factor for the progression and prognosis of COVID-19’, Diabetes/Metabolism Research and Reviews, 36(7), pp. 1–9.

Hikmawati, I. and Setiyabudi, R. (2020) ‘Hipertensi Dan Diabetes Militus Sebagai Penyakit Penyerta Utama Covid-19 Di Indonesia Hypertension and Diabetes Mellitus As Covid-19 Comorbidities in Indonesia’, Prosiding Seminar Nasional LPPM UMP, pp. 95–100.

Kelana, A.I., Ikawati, Z. and Wiedyaningsih, C. (2021) ‘Clinical Characteristic and Antibiotic Patterns among Coronavirus Disease 2019 In-patient Wava Husada Hospital Malang’, Indonesian Journal of Clinical Pharmacy, 10(4), pp. 321–329.

Kemenkes RI (2020a) Pedoman Dan Standar Etik Penelitian Dan Pengembangan Kesehatan Nasional. Jakarta.

Kemenkes RI (2020b) Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Jakarta.

Kemenkes RI (2023) Infeksi Emerging (Media Informasi Resmi Terkini Penyakit Infeksi Emerging). Jakarta.

Lisni, I., Mujianti, D. and Anggriani, A. (2021) ‘Profil Antibiotik Untuk Pengobatan Pasien Covid-19 Di Suatu Rumah Sakit Di Bandung’, Jurnal Ilmiah Farmako Bahari, 12(2), p. 99.

Nawangsari, H. (2021) ‘Hubungan Karakteristik Individu Dengan Pengetahuan Tentang Pencegahan Coronavirus Disease 2019 Pada Masyarakat Di Kecamatan Pungging Mojokerto’, Sentani Nursing Journal, 4(1), pp. 46–51.

Ningrum, E.P., Pratiwi, A.D.E. and Adhityasmara, D. (2021) ‘Penggunaan Antibiotika pada Pasien Covid-19 di Rumah Sakit “A” Kota Semarang’, Jurnal Ilmiah Cendekia Eksakta, pp. 105-110.

Nurwanto, P.D.C. (2020) ‘Pengaruh Pengetahuan Dan Kebiasaan Lansia Terhadap Perilaku Pencegahan Penyakit COVID-19’, 1, pp. 83–89.

Paluseri, A. et al. (2021) ‘Analisis efektivitas biaya penggunaan antibiotik levofloksasin dan azitromisin pada pasien penderita’, 12(1), pp. 50–54.

Rahayu, C. et al. (2013) ‘ Analisis Efektivitas Biaya Penggunaan Antibiotik Pasien Sepsis di Rumah Sakit di Bandung’, 2.

Raini, M. (2016) ‘ Antibiotik Golongan Fluorokuinolon: Manfaat dan Kerugian’, Media Penelitian Dan Pengembangan Kesehatan, 26(3), pp. 163–174.

Rina, A. and Eff, Y. (2021) ‘SARS-Cov-2: Virologi dan Target Obat SARS-Cov-2: Virology and Drug Targets’, Archives Pharmacia, 3, p. 73.

Sinto, R. (2020) ‘Peran Penting Pengendalian Resistensi Antibiotik pada Pandemi COVID-19’, Jurnal Penyakit Dalam Indonesia, 7(4), pp. 194–195.

Yulian, I., Widiatmoko, A. and Retnani, D.P.D. (2018) ‘Terapi Eksisi Pada Neurofibroma’, Majalah Kesehatan(Laporan Kasus), 5(3), pp. 181–189.




DOI: https://doi.org/10.31596/cjp.v7i2.245

Refbacks

  • There are currently no refbacks.


Journal Indexed by:

Google Scholar OneSearch Garuda Ristekdikti PKP Index Crossref

Copyright of Cendekia Journal of Pharmacy. ISSN: 2599-2163 (Print) dan 2599-2155 (Online).

Creative Commons License
This work is licensed under a Creative Commons Attribution 2.0 Generic License. Web Analytics View My Stats